Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01593254
Recruitment Status : Active, not recruiting
First Posted : May 8, 2012
Last Update Posted : February 6, 2018
ICON Clinical Research
Molecular MD
Q2 Solutions
Donald E. Morisky
MD Anderson Symptom Inventory (MDASI-CML)
OBiS, Inc
Steering Committee
Information provided by (Responsible Party):
Bristol-Myers Squibb

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Primary Completion Date : November 8, 2017
  Estimated Study Completion Date : February 17, 2022